Key facts
- Mabgeek Biotechnology’s last known valuation is $367.8M (Jul 2025).
- It has raised $96.3M; the latest was IPO in Jul 2025.
- Notable investors include Shandong Finance Group, Shanghai Zhangjiang Science & Technology Venture Capital, DPH Capital, GF Qianhe, Optics Valley Financial Holdings Group — 16 tracked in total.
- Status: In IPO Registration.
Investors
16+- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Mabgeek Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Mabgeek Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mabgeek Biotechnology
Developer of a new antibody biotechnology designed to overcome autoimmune diseases. The company focuses on research and development of antibody drugs for allergic inflammatory diseases and autoimmune diseases, enabling patients to receive effective treatment and improve their health conditions.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2016
- Employees
- 43
- Website
- mabgeek.com/
- Ownership
- In IPO Registration
Mabgeek Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mabgeek Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mabgeek Biotechnology in its N-PORT filings yet. We sweep new filings monthly.